Trial · NCT00528450
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
NCT00528450, Phase 2, Terminated, Memorial Sloan Kettering Cancer Center; results first posted 2016-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia. Trials, record NCT00528450. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00528450
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
- NCT number
- NCT00528450
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Leukemia
- Interventions
- arsenic trioxide, idarubicin, tretinoin
- First posted
- 2007-09-12
- Last updated
- 2016-01-29
- Results first posted
- 2016-01-29
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Molecular Remission Rate | 2 years | \# of patients with Complete Remission |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Molecular Remission Rate | 2 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Molecular Remission Rate | All Patients | 1 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Patients | 1 | |
| Overall Study | COMPLETED | All Patients | 1 | |
| Overall Study | NOT COMPLETED | All Patients | 0 |
Source ClinicalTrials.gov
Adverse events19
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Blood and lymphatic system disorders | All Patients | 1 | 1 | 1 |
| other | AST, SGOT | Blood and lymphatic system disorders | All Patients | 1 | 1 | 1 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | All Patients | 1 | 1 | 1 |
| other | Bilirubin (hyperbilirubinemia) | Metabolism and nutrition disorders | All Patients | 1 | 1 | 1 |
| other | Dizziness | Nervous system disorders | All Patients | 1 | 1 | 1 |
| other | Glucose, high (hyperglycemia) | Metabolism and nutrition disorders | All Patients | 1 | 1 | 1 |
| other | Hemoglobin | Blood and lymphatic system disorders | All Patients | 1 | 1 | 1 |
| other | Infection, other | Infections and infestations | All Patients | 1 | 1 | 1 |
| other | Leukocytes (total WBC) | Blood and lymphatic system disorders | All Patients | 1 | 1 | 1 |
| other | Lymphopenia | Blood and lymphatic system disorders | All Patients | 1 | 1 | 1 |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Patients | ||
| Total, other adverse events | All Patients | 1 | 1 |
| Total, serious adverse events | All Patients | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | Rudin, Charles M. | SLOAN-KETTERING INST CAN RESEARCH | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00528450
GET https://conductscience.org/api/trials/v1/NCT00528450/registered